Search
Molecular profiling of the tumour immune microenvironment (TIME) has enabled the rational choice of immunotherapies in some adult cancers. In contrast, the TIME of paediatric cancers is relatively unexplored. We speculated that a more refined appreciation of the TIME in childhood cancers, rather than a reliance on commonly used biomarkers such as tumour mutation burden (TMB), neoantigen load and PD-L1 expression, is an essential prerequisite for improved immunotherapies in childhood solid cancers.
Rearrangements of the Mixed Lineage Leukemia (MLL/KMT2A) gene are present in approximately 10% of acute leukemias and characteristically define disease with poor outcome.
At The Kids Research Institute Australia, our Brain Tumour Research team is leading the charge to change the story for children diagnosed with brain cancer by working on safer, more effective treatments.
On Monday 1 September, childhood cancer researcher Jacob Byrne is lacing up his running shoes and taking the first steps of an extraordinary challenge: 30 marathons in 30 days across Perth.
The WA Kids Cancer Centre has secured $1.1 million in funding from the Medical Research Future Fund’s (MRFF) Paediatric Brain Cancer Research Stream 2 to develop more effective and less toxic treatments for rare brain cancers in infants.
Personalised medicine for childhood cancers in West Australia is a step closer thanks to the Zero Childhood Cancer program’s state clinical trial launched today
Dr Nick Gottardo, Co-Head of The Kids Research Institute Australia's Brain Tumour Research Team, has been announced a nominee for the 2018 WA Australian of the Year Award
The Kids Research Institute Australia's Brain Tumour Research team will develop and implement cutting-edge technologies to revolutionise the speed of brain cancer diagnosis for WA children, thanks to more than $200,000 from Telethon.
Eight childhood cancer researchers have been awarded over $2 million in transformative grants from Cancer Council WA to advance their pioneering work in improving cancer treatments and outcomes for patients in Western Australia and around the world.
With immune checkpoint therapy (ICT) having reshaped the treatment of many cancers, the next frontier is to identify and develop novel combination therapies to improve efficacy. Previously, we and others identified beneficial immunological effects of the vitamin A derivative tretinoin on anti-tumour immunity.